Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery

被引:15
|
作者
Paik, E. Sun [1 ]
Lee, Yoo-Young [1 ]
Shim, Minhee [1 ]
Choi, Hyun Jin [1 ]
Kim, Tae-Joong [1 ]
Choi, Chel Hun [1 ]
Lee, Jeong-Won [1 ]
Kim, Byoung-Gie [1 ]
Bae, Duk-Soo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea
关键词
neoplasms; ovarian neoplasms; prognosis; recurrence; residual; METASTATIC MUCINOUS ADENOCARCINOMAS; CHEMOTHERAPY; SURVIVAL; STATISTICS; PREDICTORS; RESECTION; RISK;
D O I
10.1111/ajo.12529
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveThe aim of this study was to analyse patterns and timing of recurrence and their association with clinical outcomes in recurrent epithelial ovarian cancer (EOC) patients with no gross residual disease after primary debulking surgery (PDS). MethodsThis study was conducted on 303 EOC patients with no residual disease after PDS who were treated at the Samsung Medical Center from 2002 to 2012. By reviewing electronic medical records, information on date of clinical/pathological recurrence and pattern of disease presentation for each relapse were retrieved. ResultsWithin a median follow-up of 53 months (range 3-156), 88 recurrences (29.0%) and 28 cancer-related deaths (9.2%) were observed. Most of the recurrences were distant, discrete and transcoelomic. After complete cytoreduction, the initial stage was associated with location of recurrence, but not with recurrence patterns. Complete cytoreduction reduced the number of recurrences, but it did not affect timing of recurrence. In multivariate analysis for overall survival (OS), patients with distant recurrence, diffuse carcinomatosis and mixed spread pattern of transcoelomic, lymphatic and haematogenous recurrence were found to have higher risk. ConclusionsWe found that timing of recurrence was not affected by complete cytoreduction. Location, type and pattern of recurrence were also significant prognostic factors for OS, in addition to known prognostic predictors such as platinum sensitivity.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 50 条
  • [1] Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis
    Ghirardi, V
    Moruzzi, M. C.
    Bizzarri, N.
    Vargiu, V.
    D'Indinosante, M.
    Garganese, G.
    Pasciuto, T.
    Loverro, M.
    Scambia, G.
    Fagotti, A.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 209 - 213
  • [2] Chemotherapy delay after primary debulking surgery for ovarian cancer
    Seagle, Brandon-Luke L.
    Butler, Sharlay K.
    Strohl, Anna E.
    Nieves-Neira, Wilberto
    Shahabi, Shohreh
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 260 - 265
  • [3] Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
    Sorensen, Sarah Mejer
    Hogdall, Claus
    Mosgaard, Berit Jul
    Dalgaard, Maya Isabella Riise
    Jensen, Mai Partridge
    Fuglsang, Katrine
    Schnack, Tine Henrichsen
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (03) : 334 - 343
  • [4] Primary site disease and recurrence location in ovarian cancer patients undergoing primary debulking surgery vs. interval debulking surgery
    Andrea, Capozzi Vito
    Uccella, Stefano
    Sozzi, Giulio
    Ceccaroni, Marcello
    Mautone, Daniele
    Armano, Giulia
    Franchi, Massimo
    Chiantera, Vito
    Berretta, Roberto
    EJSO, 2021, 47 (05): : 1075 - 1082
  • [5] Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer
    Mitsopoulos, Vasileios
    Innamaa, Anni
    Lippiatt, Jonathan
    Collins, Sarah
    Biliatis, Ioannis
    ANTICANCER RESEARCH, 2022, 42 (04) : 2003 - 2008
  • [6] Predictors of residual disease after debulking surgery in advanced stage ovarian cancer
    Abbas-Aghababazadeh, Farnoosh
    Sasamoto, Naoko
    Townsend, Mary K.
    Huang, Tianyi
    Terry, Kathryn L.
    Vitonis, Allison F.
    Elias, Kevin M.
    Poole, Elizabeth M.
    Hecht, Jonathan L.
    Tworoger, Shelley S.
    Fridley, Brooke L.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer
    Tsolakidis, D.
    Amant, F.
    Van Gorp, T.
    Leunen, K.
    Neven, P.
    Vergote, I.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 489 - 496
  • [8] Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer - a retrospective cohort study
    Maricic, Slobodan
    Mandic, Aljosa
    Dejanovic, Ninoslav
    Kladar, Nebojsa
    Popovic, Marina
    Ivkovic-Kapicl, Tatjana
    Gutic, Bojana
    Kokanov, Dunja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1193 - 1199
  • [9] The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery
    Rutten, I. J. G.
    Ubachs, J.
    Kruitwagen, R. F. P. M.
    van Dijk, D. P. J.
    Beets-Tan, R. G. H.
    Massuger, L. F. A. G.
    Damink, S. W. M. Olde
    Van Gorp, T.
    EJSO, 2017, 43 (04): : 717 - 724
  • [10] Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?
    Markauskas, Algirdas
    Mogensen, Ole
    Christensen, Rene dePont
    Jensen, Pernille Tine
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (08) : 1420 - 1428